Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2027
Abstract: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). While ATTR‐ACT was not designed for a dose‐specific assessment, further analysis from ATTR‐ACT and its long‐term… read more here.
Keywords: attr act; attr; tafamidis transthyretin; transthyretin cardiomyopathy ... See more keywords